Related Party Transactions |
6 Months Ended | ||
|---|---|---|---|
Jun. 30, 2025 | |||
| Related Party Transactions [Abstract] | |||
| Related Party Transactions |
The Company has entered into various research, development, license and supply agreements with PeriNess Ltd. (“PeriNess”), Serum Institute and Pharmsynthez, each a related party whose relationship has not materially changed from that disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 18, 2025, as amended on April 29, 2025 and May 13, 2025. The Company paid PeriNess approximately $55,000 during the six months ended June 30, 2025. As of June 30, 2025 and December 31, 2024, approximately $50,000 was recorded as an advanced payment and included in Prepaid expenses and other. In addition, approximately $22,000 and $8,000 was reflected in accounts payable as of June 30, 2025 and December 31, 2024, respectively. No amounts were incurred in connection with agreements with Serum Institute and Pharmsynthez during the six months ended June 30, 2025 and 2024.
During the first quarter of 2025, the Company entered into a Consulting Agreement with Dr. Dmitry Genkin, Chairman of our Board of Directors, to provide consulting services to the Company’s DNase-based oncology program. This agreement was effective January 1, 2025 and the Company paid Dr. Genkin approximately $0.1 million and $0.2 million during the three and six months ended June 30, 2025, of which approximately $30,000 was reflected within accounts payable as of June 30, 2025. Dr. Genkin does not receive any fees for his service as a member of the Board of Directors. |